PMID- 31545285
OWN - NLM
STAT- MEDLINE
DCOM- 20200204
LR  - 20200204
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 118
DP  - 2019 Oct
TI  - Descending-SHIP2-mediated radiosensitivity enhancement through PI3K/Akt signaling 
      pathway in laryngeal squamous cell carcinoma.
PG  - 109392
LID - S0753-3322(19)33071-9 [pii]
LID - 10.1016/j.biopha.2019.109392 [doi]
AB  - Laryngeal squamous cell carcinoma (LSCC) is the major type of laryngeal 
      carcinoma. SHIP2 plays a critical role in malignant tumors and is associated with 
      activation of PI3K/Akt signaling pathway. Here, we aimed to explore the impacts 
      of SHIP2 on LSCC Hep-2 cells and the relationship between SHIP2 and radiotherapy. 
      SHIP2 knockdown impairs cell proliferation, invasion, migration and promotes cell 
      apoptosis in this study, suggesting the oncogenic role of SHIP2 in laryngeal 
      cancer. Radiation not only has the similar effect on laryngeal cancer as SHIP2 
      knockdown, but also causes significant cell cycle G2 arrest, all of which can be 
      significantly enhanced by SHIP2 knockdown. This enhancement effect cause by SHIP2 
      knockdown derive from the inactivation of PI3K/Akt signaling pathway along with 
      its downstream proteins. Our finding revealed a novel mechanism for sensitivity 
      to radiotherapy caused by SHIP2 knockdown that called descending-SHIP2-mediated 
      radiosensitivity enhancement (DSMRSE).
CI  - Copyright (c) 2019 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Tang, Tian
AU  - Tang T
AD  - Department of Oncology, RenMin Hospital of Wuhan University, Wuhan, China.
FAU - Xiao, Zhu-Ya
AU  - Xiao ZY
AD  - Department of Oncology, RenMin Hospital of Wuhan University, Wuhan, China.
FAU - Shan, Guang
AU  - Shan G
AD  - Department of Urology, RenMin Hospital of Wuhan University, Wuhan, China.
FAU - Lei, Hong-Bo
AU  - Lei HB
AD  - Department of Oncology, RenMin Hospital of Wuhan University, Wuhan, China. 
      Electronic address: whuleihongbo@163.com.
LA  - eng
PT  - Journal Article
DEP - 20190829
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Small Interfering)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 3.1.3.86 (INPPL1 protein, human)
RN  - EC 3.1.3.86 (Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases)
SB  - IM
MH  - Apoptosis
MH  - Carcinoma, Squamous Cell/*metabolism/pathology
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Humans
MH  - Laryngeal Neoplasms/*metabolism/pathology
MH  - Neoplasm Invasiveness
MH  - Phosphatidylinositol 3-Kinases/*metabolism
MH  - Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases/genetics/*metabolism
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - RNA, Messenger/genetics/metabolism
MH  - RNA, Small Interfering/metabolism
MH  - *Radiation Tolerance
MH  - Signal Transduction
OTO - NOTNLM
OT  - Descending-SHIP2-mediated radiosensitivity enhancement
OT  - Laryngeal squamous cell carcinoma
OT  - PI3K/Akt
OT  - Radiosensitivity
OT  - SHIP2
OT  - pAKT
EDAT- 2019/09/24 06:00
MHDA- 2020/02/06 06:00
CRDT- 2019/09/24 06:00
PHST- 2019/07/01 00:00 [received]
PHST- 2019/08/17 00:00 [revised]
PHST- 2019/08/22 00:00 [accepted]
PHST- 2019/09/24 06:00 [entrez]
PHST- 2019/09/24 06:00 [pubmed]
PHST- 2020/02/06 06:00 [medline]
AID - S0753-3322(19)33071-9 [pii]
AID - 10.1016/j.biopha.2019.109392 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2019 Oct;118:109392. doi: 10.1016/j.biopha.2019.109392. Epub 
      2019 Aug 29.